

# Program

08:30 Registration & refreshments

---

## Prevention of disease

09:00 **Towards immoridity: the link between AIDS, influenza, Alzheimer's disease and aging**

**Frank de Wolf**

Global Head, Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson; Professor of Clinical Retrovirology, Imperial College London, United Kingdom

09:15 **A world of disease as a historical artifact**

**William N. Hait**

Global Head, Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson

09:30 **Transforming health through innovation**

**Paul Stoffels**

Executive Vice President, Chief Scientific Officer, Johnson & Johnson

---

## HIV/AIDS as a model for disease prediction and prevention

**Chair: Hanneke Schuitemaker**

Vice President, Viral Vaccine Discovery and Translational Medicine, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson

09:45 **Towards curing and preventing AIDS**

**Dan Barouch**

Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center; Professor of Medicine, Harvard Medical School, Boston, MA, United States

10:10 **Adenovirus immortalization of human cells: the origin of the PER.C6® cell line**

**Alex Jan van der Eb**

Emeritus Professor, Leiden University, the Netherlands

10:35 Coffee break

---

## Fighting influenza: Universal vaccines, monoclonal antibodies and drugs

**Chair: Robert Friesen**

Head of Innovation at ProQR Therapeutics, Leiden, the Netherlands

11:00 **Challenging influenza using human monoclonal antibodies against the HA stem**

**Jerry Sadoff**

Senior Advisor for Vaccine Development, Janssen Vaccines and Prevention, Janssen Pharmaceutical Companies of Johnson & Johnson

11:25 **Using HA stem antibodies as a template for small molecules**

**Maria van Dongen**

Director, Discovery Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson

11:50 **Structure-assisted design of a universal vaccine and therapeutics against influenza virus**

**Ian Wilson**

Hansen Professor, Structural Biology and Chair, Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States

---

# Program

12:15 Lunch

---

## Pharmaceutical innovation

13:30 **The prevention opportunity: How can the pharmaceutical industry rise to the challenge?**

**Richard Mason**

Head, Johnson & Johnson Innovation, London, United Kingdom

---

## Alzheimer's disease and dementia: The prototype of an age-related disease

**Chair: Albert Hofman**

Chair, Department of Epidemiology, and Stephen B. Kay Family Professor of Public Health and Clinical Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

13:50 **The role of computer-based simulation in the optimal design of clinical trials for disease therapies**

**Sir Roy Anderson**

Professor of Infectious Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London; and Director of the London Centre for Neglected Tropical Disease Research, London, United Kingdom

14:15 **The impact of modifiable risk factors on dementia and Alzheimer's disease**

**Arfan Ikram**

Professor of Neuroepidemiology and Chair, Department of Epidemiology, Erasmus MC Rotterdam, the Netherlands; Adjunct Professor of Epidemiology, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

14:40 **Immunological memory to the brain protein tau in symptom-free individuals: a road to effective prevention of Alzheimer's disease**

**Jaap Goudsmit**

Professor of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Professor of Natural History and Pathogenesis of Neurodegenerative Diseases, Academic Medical Center of the University of Amsterdam, the Netherlands

15:05 Tea break

---

## Biomarkers for biological age: determinants of morbidity and mortality

**Chair: Ben Wiegand**

Global Head, World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson & Johnson

15:30 **The pace of aging: implications for clinical trials and extension of healthspan**

**Daniel Belsky**

Assistant Professor of Medicine, Duke University, Durham, NC, United States

15:55 **Genetic, physiological and lifestyle predictors of morbidity and mortality**

**Albert Hofman**

Chair, Department of Epidemiology, and Stephen B. Kay Family Professor of Public Health and Clinical Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

16:20 **Epigenetic markers for all-cause mortality and morbidity**

**Frank de Wolf**

Global Head, Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson; Professor of Clinical Retrovirology, Imperial College London, United Kingdom

---

## Closing remarks

16:45 **A world without disease—what's needed?**

**Ben Wiegand**

Global Head, World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson & Johnson

---

17:00 Drinks and hors d'oeuvres